FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO\	/AL
OMB Number:	3235-0287
Estimated average but	rden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Responses	3)														
1. Name and Address of Reporting Person * Kotzin Brian L.				2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BOULEVARD				3. Date of Earliest Transaction (Month/Day/Year) 05/23/2019							Officer (give	e title below)	Oth	er (specify below	<i>i</i>)	
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _ Form filed by More than One Reporting Person					
(Cit	y)	(State)	(Zip)			Ta	ble I	- Non-Deriv	vative Secu	rities	Acquired	, Disposed	of, or Bene	ficially Own	ed	
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea		2A. Deemed Execution I any (Month/Day		te, if C	(Instr. 8)		4. Securities Acqu (A) or Disposed of (Instr. 3, 4 and 5)		f (D) Own Tran	5. Amount of Securities Ben Dwned Following Reported Fransaction(s) Instr. 3 and 4)		l (Ownership Form: H Direct (D)	7. Nature of Indirect Beneficial Ownership Instr. 4)		
							Code	e V A) or D)	Price				(I) (Instr. 4)	
Reminder:								Person in this f	s who res	ot re	quired to	respond	unless the	tion contair e form	ed SEC 1	474 (9-02)
	•			Derivati	ive Sec	curities	Acqu	Personing this followed the display the di	s who res form are n s a currer	ot re itly va Benefi	quired to alid OMB icially Ow	respond control n	unless the		ed SEC 1	474 (9-02)
1. Title of	2. Conversion	3. Transaction	Table II - 3A. Deemed Execution Date, if	Derivati (e.g., pur 4. Transac Code	ive Sects, call 5 tion o S O O O O O O O O O O O O O O O O O O	Numb f Deriva ecurities cquired r Dispo f (D)	Acquerants, er ative es d (A) sed	Personation this followed display	s who restorm are not a current seed of, or leavertible services and the current seed of the current seed	not rently van	quired to alid OMB icially Ow	respond control n ned d Amount ing	unless the umber.	9. Number of Derivative Securities Beneficially Owned Following Reported	f 10. Ownersh Form of Derivativ Security: Direct (E or Indirec	11. Natur of Indired Beneficia Ownersh (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if any	Derivati (e.g., pur 4. Transac Code	ive Sects, call 5 tion o S O O O O O O O O O O O O O O O O O O	eurities s, warr . Numb f Deriva ecuritie .cquirec r Dispo f (D)	Acquants, er attive es d (A) sed 4,	Personin this findisplay	s who restorm are not a current seed of, or seed of, o	Beneficeurit	quired to alid OMB icially Ow ties) 7. Title and of Underly Securities	respond control n ned d Amount ing	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following	f 10. Ownersh Form of Derivativ Security: Direct (E or Indirec	11. Natur of Indired Beneficia Ownersh (Instr. 4)

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Kotzin Brian L. RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BOULEVARD SOUTH SAN FRANCISCO, CA 94080	X					

Signatures

/s/ Dolly Vance (Attorney-in-Fact)	05/24/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares shall vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.